Efficacy and safety of laser‐related therapy for melasma: A systematic review and network meta‐analysis
Journal of Cosmetic Dermatology · 2023
DOI: 10.1111/jocd.16006 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Cosmetic Dermatology, 2023. Verfasst von Wenyi Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. Hauptthemen laut MEDLINE: Melanosis, Lasers, Solid-State, Low-Level Light Therapy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Affiliated Hospital of Chengdu University of Chinese Medicine.
Abstract (Originalsprache)
Background
Melasma is a prevalent, persistent hyperpigmentation disorder that negatively affects the psychological health of patients. However, the treatment outcome remains unsatisfactory due to the complexity of pathogenesis, recurrence characteristics, and relatively high morbidity.
Objectives
To compare the performance of laser‐related therapies in improving the melasma area severity index (MASI) score of melasma and the occurrence of adverse effects by network meta‐analysis (NMA).
Methods
From the inception to November 2022, eligible randomized controlled trials were identified. Two investigators independently searched relevant studies from PUBMED, EMBASE, and the Cochrane Library database.
Results
A total of 39 clinical studies with 1394 participants were eligible for enrollment. For efficacy, the NMA demonstrated that Q‐switched Nd: YAG laser + topical medications (QSND+TM) was superior to Q‐switched Nd:YAG laser (QSND) [MD = −4.21 (−6.80, −1.63)], Er: YAG laser + topical medications (ERYL+TM) [MD = ‐3.52 (−6.84, −0.19)], and picosecond laser + topical medications (PICO+TM) [MD = −4.80 (−9.33, −0.27)]. The microneedling + topical medications (MN+TM) was superior to picosecond laser (PICO) [MD = −5.26 (−10.44, −0.08)] and topical medications (TM) [MD = −5.22 (−9.20, −1.23)]. The top five of the surface under the cumulative ranking curve value (SUCRA) are Q‐switched Nd:YAG laser + topical medications (QSND+TM 85.9%), oral tranexamic acid (oTA 80.1%), microneedling + topical medications (MN+TM 79.7%), Q‐switched Nd:YAG laser + intense pulse light (QSND+IPL 78.9%), and fractional carbon dioxide laser + topical medications (FCDL+TM 70.5%).
Conclusions
In conclusion, the Qs‐Nd:YAG laser with topical medications is the first choice for treating melasma according to the SUCRA value. Among the three treatment modalities, namely MN + TM, PICO, and TM, our recommendation favors MN+TM as the superior choice for enhancing the curative efficacy in melasma. However, the actual clinical choice should also take into account the adverse effects, the skin type of the patient, the duration of the disease, and other relevant factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
ORCID-Profile: Wenyi Ma, Nana Luo, Pingsheng Hao
Förderung
- the Affiliated Hospital of Chengdu University of Chinese Medicine
Zitieren
APA
Ma, W., Gao, Q., Liu, J., Zhong, X., Xu, T., Wu, Q., Cheng, Z., Luo, N., & Hao, P. (2023). Efficacy and safety of laser‐related therapy for melasma: A systematic review and network meta‐analysis. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16006
Vancouver
Ma W, Gao Q, Liu J, Zhong X, Xu T, Wu Q, et al. Efficacy and safety of laser‐related therapy for melasma: A systematic review and network meta‐analysis. Journal of Cosmetic Dermatology. 2023. doi:10.1111/jocd.16006
BibTeX
@article{Ma2023,
author = {Ma, Wenyi and Gao, Qian and Liu, Jinghua and Zhong, Xiaojing and Xu, Tongtong and Wu, Qinyao and Cheng, Zilin and Luo, Nana and Hao, Pingsheng},
title = {Efficacy and safety of laser‐related therapy for melasma: A systematic review and network meta‐analysis},
journal = {Journal of Cosmetic Dermatology},
year = {2023},
doi = {10.1111/jocd.16006}
}
EUVIMED